TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Assessment of an School-based Intervention in Eating Habits and Physical Activity in Schoolchildren: the AVall Study.
Brief Summary: The objective of the study is to evaluate the efficacy of an intervention on food habits and physical activity in school-age children.


Options:
A: Arm Label: Educational intervention, Control; Type: EXPERIMENTAL; Interventions: Other: Educational program | Arm Label: Educational program; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Educational program; Assigned to Arm(s): Educational intervention, Control
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Advice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Dietary Advice; Assigned to Arm(s): Intervention
C: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Wellness Plan; Type: EXPERIMENTAL; Interventions: Behavioral: Wellness Action Plan | Intervention Type: BEHAVIORAL; Name: Wellness Action Plan; Assigned to Arm(s): Wellness Plan
D: Arm Label: Lower protein formula; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Higher protein formula; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Lower protein formula; Higher protein formula | Arm Label: Breastfed reference group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Lower protein formula; Higher protein formula; Assigned to Arm(s): Higher protein formula, Lower protein formula

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of 3-months Open-label Treatment With PGL4001, Followed by a Randomised, Double-blind Placebo Controlled Period of 10 Days Treatment With Progestin, in Subjects With Myomas and Heavy Uterine Bleeding.
Brief Summary: This is a multicentre, Phase III, efficacy and safety open-label study with PGL4001 10mg once daily for 3 months, blinded towards the administration of progestin or placebo after end of PGL4001 treatment.


Options:
A: Arm Label: A (PGL4001 5 mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 | Arm Label: C (GnRH-agonist); Type: ACTIVE_COMPARATOR; Interventions: Drug: leuprorelin | Intervention Type: DRUG; Name: PGL4001; Assigned to Arm(s): A (PGL4001 5 mg), B (PGL4001 10mg) | Intervention Type: DRUG; Name: leuprorelin; Assigned to Arm(s): C (GnRH-agonist)
B: Arm Label: ulipristal acetate -20 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 20 mg | Arm Label: ulipristal acetate - 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: ulipristal acetate 10 mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Pre-ulipristal acetate 10 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-ulipristal acetate 20 mg; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Pre-placebo; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: ulipristal acetate 20 mg; Assigned to Arm(s): ulipristal acetate -20 mg | Intervention Type: DRUG; Name: ulipristal acetate 10 mg; Assigned to Arm(s): ulipristal acetate - 10 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: A (PGL4001 5mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 (ulipristal) and iron | Arm Label: B (PGL4001 10mg); Type: EXPERIMENTAL; Interventions: Drug: PGL4001 (ulipristal) and iron | Arm Label: C (placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: PGL4001 matching placebo and iron | Intervention Type: DRUG; Name: PGL4001 (ulipristal) and iron; Assigned to Arm(s): A (PGL4001 5mg) | Intervention Type: DRUG; Name: PGL4001 matching placebo and iron; Assigned to Arm(s): C (placebo) | Intervention Type: DRUG; Name: PGL4001 (ulipristal) and iron; Assigned to Arm(s): B (PGL4001 10mg)
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin | Intervention Type: DRUG; Name: PGL4001, placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multicentre, Clinical Study Investigating the Efficacy and Safety of 3-months Open-label Treatment With PGL4001, Followed by a Randomised, Double-blind Placebo Controlled Period of 10 Days Treatment With Progestin, in Subjects With Myomas and Heavy Uterine Bleeding.
Brief Summary: This is a multicentre, Phase III, efficacy and safety open-label study with PGL4001 10mg once daily for 3 months, blinded towards the administration of progestin or placebo after end of PGL4001 treatment.


Options:
A: Arm Label: Mifepristone 2.5 mg daily for three months; Type: EXPERIMENTAL; Interventions: Drug: Oral administration of mifepristone 2.5 mg daily for three months | Arm Label: Mifepristone 5 mg daily for three months; Type: EXPERIMENTAL; Interventions: Drug: Oral administration of mifepristone 5 mg daily for three months | Intervention Type: DRUG; Name: Oral administration of mifepristone 2.5 mg daily for three months; Assigned to Arm(s): Mifepristone 2.5 mg daily for three months | Intervention Type: DRUG; Name: Oral administration of mifepristone 5 mg daily for three months; Assigned to Arm(s): Mifepristone 5 mg daily for three months
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, placebo | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: PGL4001, progestin | Intervention Type: DRUG; Name: PGL4001, placebo; Assigned to Arm(s): A | Intervention Type: DRUG; Name: PGL4001, progestin; Assigned to Arm(s): B
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Asoprisnil | Arm Label: 4; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Asoprisnil; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 4
D: Arm Label: Ulipristal acetate (PGL4001) 5mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 5 mg | Arm Label: Ulipristal acetate (PGL4001) 10mg; Type: EXPERIMENTAL; Interventions: Drug: PGL4001 10 mg | Intervention Type: DRUG; Name: PGL4001 5 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 5mg | Intervention Type: DRUG; Name: PGL4001 10 mg; Assigned to Arm(s): Ulipristal acetate (PGL4001) 10mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Care Guides: Can Trained Laypersons Help Manage Chronic Disease? A Randomized Trial.
Brief Summary: Trained lay persons ("care guides") working with chronic disease patients and their providers can help outpatients with diabetes, hypertension, and congestive heart failure achieve standard clinical care goals


Options:
A: Arm Label: Diabetes Educational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Education | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Diabetes Education; Assigned to Arm(s): Diabetes Educational Intervention
B: Arm Label: care guide; Type: EXPERIMENTAL; Interventions: Behavioral: education and care guide | Arm Label: no care guide; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education only | Intervention Type: BEHAVIORAL; Name: education and care guide; Assigned to Arm(s): care guide | Intervention Type: BEHAVIORAL; Name: education only; Assigned to Arm(s): no care guide
C: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: In Home Health Messaging Device | Intervention Type: BEHAVIORAL; Name: In Home Health Messaging Device; Assigned to Arm(s): Arm 1
D: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Telemedicine group; Type: ACTIVE_COMPARATOR; Interventions: Device: Telemedicine system | Intervention Type: DEVICE; Name: Telemedicine system; Assigned to Arm(s): Telemedicine group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Care Guides: Can Trained Laypersons Help Manage Chronic Disease? A Randomized Trial.
Brief Summary: Trained lay persons ("care guides") working with chronic disease patients and their providers can help outpatients with diabetes, hypertension, and congestive heart failure achieve standard clinical care goals


Options:
A: Arm Label: care guide; Type: EXPERIMENTAL; Interventions: Behavioral: education and care guide | Arm Label: no care guide; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education only | Intervention Type: BEHAVIORAL; Name: education and care guide; Assigned to Arm(s): care guide | Intervention Type: BEHAVIORAL; Name: education only; Assigned to Arm(s): no care guide
B: Arm Label: Conventional rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Conventional rehabilitation. | Arm Label: Novel rehabilitation approach; Type: EXPERIMENTAL; Interventions: Behavioral: Novel rehabilitation approach | Intervention Type: BEHAVIORAL; Name: Conventional rehabilitation.; Assigned to Arm(s): Conventional rehabilitation | Intervention Type: BEHAVIORAL; Name: Novel rehabilitation approach; Assigned to Arm(s): Novel rehabilitation approach
C: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
D: Intervention Type: BEHAVIORAL; Name: Shared Decision-Making; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Care Guides: Can Trained Laypersons Help Manage Chronic Disease? A Randomized Trial.
Brief Summary: Trained lay persons ("care guides") working with chronic disease patients and their providers can help outpatients with diabetes, hypertension, and congestive heart failure achieve standard clinical care goals


Options:
A: Arm Label: Telemedicine; Type: EXPERIMENTAL; Interventions: Procedure: Ophthalmic Telemedicine | Arm Label: Traditional Surveillance; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Ophthalmic Telemedicine; Assigned to Arm(s): Telemedicine
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Toolkit | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Toolkit; Assigned to Arm(s): Intervention | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: care guide; Type: EXPERIMENTAL; Interventions: Behavioral: education and care guide | Arm Label: no care guide; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: education only | Intervention Type: BEHAVIORAL; Name: education and care guide; Assigned to Arm(s): care guide | Intervention Type: BEHAVIORAL; Name: education only; Assigned to Arm(s): no care guide
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Device: Electronic feedback system on diabetes care | Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Electronic feedback system on diabetes care; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I, Double Blind, Parallel-Group, Multi-center, Gene Expression (Synthesis of FGF-1 mRNA) and Tolerability Study of Increasing Single Dose of NV1FGF Administered by Intra-Muscular Injection in Subjects With Severe Peripheral Artery Occlusive Disease (PAOD) Planned to Undergo Amputation Above the Ankle
Brief Summary: The primary objective is to evaluate the transgene expression (synthesis of FGF-1 mRNA) in injected tissue, at injection site, after Intra Muscular (IM) administration of increasing single doses of NV1FGF.

Secondary objectives :

* To evaluate the safety and tolerability of IM administration of increasing single doses of NV1FGF
* To evaluate the transgene expression (FGF-1 protein) in injected tissues (injection site and remote site)
* To evaluate the presence of FGF-1 receptors in injected tissues (injection site and remote site)
* To evaluate the NV1FGF biodistribution in injected tissues (injection site and remote site), in multiple organs/tissues when appropriate, and plasma
* To evaluate the transgene expression (synthesis of FGF-1 mRNA) in injected tissue at remote site
* To collect data from plasma NV1FGF pharmacokinetics
* To evaluate healing of the amputation site


Options:
A: Arm Label: NV1FGF 500 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 2000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 4000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 2000 μg, NV1FGF 4000 μg, NV1FGF 500 μg
B: Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: bone marrow stem cells intraarterial; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow stem cells (BMC) | Arm Label: tissue repair cells intramuscular; Type: ACTIVE_COMPARATOR; Interventions: Biological: tissue repair cells (TRC) | Arm Label: tissue repair cells intraarterial; Type: ACTIVE_COMPARATOR; Interventions: Biological: tissue repair cells (TRC) | Arm Label: bone marrow stem cells intramuscular; Type: ACTIVE_COMPARATOR; Interventions: Biological: bone marrow stem cells (BMC) | Intervention Type: BIOLOGICAL; Name: tissue repair cells (TRC); Assigned to Arm(s): tissue repair cells intraarterial, tissue repair cells intramuscular | Intervention Type: BIOLOGICAL; Name: bone marrow stem cells (BMC); Assigned to Arm(s): bone marrow stem cells intraarterial, bone marrow stem cells intramuscular
C: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
D: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase I, Double Blind, Parallel-Group, Multi-center, Gene Expression (Synthesis of FGF-1 mRNA) and Tolerability Study of Increasing Single Dose of NV1FGF Administered by Intra-Muscular Injection in Subjects With Severe Peripheral Artery Occlusive Disease (PAOD) Planned to Undergo Amputation Above the Ankle
Brief Summary: The primary objective is to evaluate the transgene expression (synthesis of FGF-1 mRNA) in injected tissue, at injection site, after Intra Muscular (IM) administration of increasing single doses of NV1FGF.

Secondary objectives :

* To evaluate the safety and tolerability of IM administration of increasing single doses of NV1FGF
* To evaluate the transgene expression (FGF-1 protein) in injected tissues (injection site and remote site)
* To evaluate the presence of FGF-1 receptors in injected tissues (injection site and remote site)
* To evaluate the NV1FGF biodistribution in injected tissues (injection site and remote site), in multiple organs/tissues when appropriate, and plasma
* To evaluate the transgene expression (synthesis of FGF-1 mRNA) in injected tissue at remote site
* To collect data from plasma NV1FGF pharmacokinetics
* To evaluate healing of the amputation site


Options:
A: Arm Label: NV1FGF 500 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 2000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 4000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 2000 μg, NV1FGF 4000 μg, NV1FGF 500 μg
B: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
D: Arm Label: Riferminogene pecaplasmid; Type: EXPERIMENTAL; Interventions: Biological: riferminogene pecaplasmid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo (for riferminogene pecaplasmid) | Intervention Type: BIOLOGICAL; Name: riferminogene pecaplasmid; Assigned to Arm(s): Riferminogene pecaplasmid | Intervention Type: BIOLOGICAL; Name: Placebo (for riferminogene pecaplasmid); Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Multi-Center, Open Label, Safety and Tolerability Study of Single and Repeated Administrations of Escalating Dose(s) of NV1FGF Administered by Intra-Muscular Injection in Patients With Severe Peripheral Artery Occlusive Disease
Brief Summary: The primary objective is to evaluate safety and tolerability of single and repeated administrations of escalating doses of NV1FGF administered intramuscularly in patients with severe Peripheral Artery Occlusive Disease (PAOD), (Rutherford's Grade II, category 4 or Grade III, category 5 and 6).

Secondary objectives are:

* To determine the biological activity of NV1FGF on collateral artery development.
* To evaluate the activity of NV1FGF on hemodynamic and clinical parameters.


Options:
A: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
B: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: ALDH-br bone marrow cells vs. mononuclear bone marrow cells | Intervention Type: PROCEDURE; Name: ALDH-br bone marrow cells vs. mononuclear bone marrow cells; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
D: Arm Label: GM-CSF; Type: EXPERIMENTAL; Interventions: Drug: Granulocyte-Macrophage Stimulating Factor (GM-CSF) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Granulocyte-Macrophage Stimulating Factor (GM-CSF); Assigned to Arm(s): GM-CSF | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase I, Multi-Center, Open Label, Safety and Tolerability Study of Single and Repeated Administrations of Escalating Dose(s) of NV1FGF Administered by Intra-Muscular Injection in Patients With Severe Peripheral Artery Occlusive Disease
Brief Summary: The primary objective is to evaluate safety and tolerability of single and repeated administrations of escalating doses of NV1FGF administered intramuscularly in patients with severe Peripheral Artery Occlusive Disease (PAOD), (Rutherford's Grade II, category 4 or Grade III, category 5 and 6).

Secondary objectives are:

* To determine the biological activity of NV1FGF on collateral artery development.
* To evaluate the activity of NV1FGF on hemodynamic and clinical parameters.


Options:
A: Arm Label: Low Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Middle Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: High Dose; Type: ACTIVE_COMPARATOR; Interventions: Biological: Ad2/HIF-1α/VP16 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Saline (Placebo Control) | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Low Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): Middle Dose | Intervention Type: BIOLOGICAL; Name: Ad2/HIF-1α/VP16; Assigned to Arm(s): High Dose | Intervention Type: OTHER; Name: Saline (Placebo Control); Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): N/A
C: Arm Label: NV1FGF 500 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 2000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Arm Label: NV1FGF 4000 μg; Type: EXPERIMENTAL; Interventions: Drug: XRP0038 (NV1FGF) | Intervention Type: DRUG; Name: XRP0038 (NV1FGF); Assigned to Arm(s): NV1FGF 2000 μg, NV1FGF 4000 μg, NV1FGF 500 μg
D: Arm Label: Neovasculgen®; Type: EXPERIMENTAL; Interventions: Drug: Neovasculgen® | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Neovasculgen® | Intervention Type: DRUG; Name: Neovasculgen®; Assigned to Arm(s): Neovasculgen®, standard care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Fifteen-month, Prospective, Randomized, Active-controlled, Open-label, Flexible Dose Study of Paliperidone Palmitate Compared With Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults With Schizophrenia Who Have Been Incarcerated
Brief Summary: The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 15 months, in patients diagnosed with schizophrenia who have been incarcerated.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: paliperidone palmitate | Arm Label: 002; Type: ACTIVE_COMPARATOR; Interventions: Drug: aripiprazole | Arm Label: 003; Type: ACTIVE_COMPARATOR; Interventions: Drug: haloperidole | Arm Label: 004; Type: ACTIVE_COMPARATOR; Interventions: Drug: olanzapine | Arm Label: 005; Type: ACTIVE_COMPARATOR; Interventions: Drug: paliperidone | Arm Label: 006; Type: ACTIVE_COMPARATOR; Interventions: Drug: perphenazine | Arm Label: 007; Type: ACTIVE_COMPARATOR; Interventions: Drug: quetiapine | Arm Label: 008; Type: ACTIVE_COMPARATOR; Interventions: Drug: risperidone | Intervention Type: DRUG; Name: paliperidone; Assigned to Arm(s): 005 | Intervention Type: DRUG; Name: risperidone; Assigned to Arm(s): 008 | Intervention Type: DRUG; Name: haloperidole; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: perphenazine; Assigned to Arm(s): 006 | Intervention Type: DRUG; Name: aripiprazole; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): 007 | Intervention Type: DRUG; Name: paliperidone palmitate; Assigned to Arm(s): 001 | Intervention Type: DRUG; Name: olanzapine; Assigned to Arm(s): 004
B: Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Other: A web based-Patient Decision Aid (PtDA) (shown on the computer) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Other: A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care. | Intervention Type: OTHER; Name: A web based-Patient Decision Aid (PtDA) (shown on the computer); Assigned to Arm(s): Intervention group | Intervention Type: OTHER; Name: A web-based fact sheet (one page shown on the computer) with general information on mental health as a part of usual care.; Assigned to Arm(s): Control group
C: Arm Label: SDM care planning; Type: EXPERIMENTAL; Interventions: Other: Shared Decision-Making educational training | Intervention Type: OTHER; Name: Shared Decision-Making educational training; Assigned to Arm(s): SDM care planning
D: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Introduction Seminar; Type: OTHER; Interventions: Other: A psychoeducational group intervention. | Intervention Type: OTHER; Name: A psychoeducational group intervention.; Assigned to Arm(s): Introduction Seminar

Answer: A